A well known and well accepted example is high blood pressure (surrogate) and cardiovascular disease (primary outcome). Reduction of an elevated blood pressure, in and of itself, produces no immediate benefit to an individual. It doesn't improve physical functioning or other aspects of quality of life. It has been amply demonstrated, however, that lowering blood pressure reduces the risks of heart attack and stroke (Collins et al., 1990; SHEP Cooperative Research Group, 1991; Dahlof et al., 1991 (Byar, 1973) . Another even more dramatic example in a non-cancer context was the finding in a double-blind randomised trial by The Cardiac Arrhythmia Suppression Trial (CAST) Investigators (1989) that drugs that were effective in preventing arrhythmias in patients recovering from a myocardial infarction were associated with higher mortality, despite the fact that arrhythmias are known to be associated with poorer survival.
The converse may occur; all or part of a drug's benefit may not be mediated through the proposed surrogate so that the treatment effect may be underestimated if the true outcome is not assessed. In a recent study, interferon y for chronic granulomatous disease was found to be highly efficacious in protecting against the occurrence of serious bacterial infections, but the laboratory markers that had been thought to mediate the utility of this therapy were unaffected (The International Chronic Granulomatous Disease Cooperative Study Group, 1991) .
The second problem is that a surrogate that appears appropriate to evaluate one class of treatments may not be appropriate to evaluate other treatments with different mechanisms of action. If treatments are interrupting disease via different mechanisms, there is no guarantee that a more proximal endpoint will equally well reflect the effects of these treatments. This problem may not be a serious one for tumour response, the prototype surrogate endpoint for cancer studies, since whatever the mechanism of action, tumour growth must be thwarted in order to improve ultimate outcome. It may, however, be of more concern for laboratory markers or other less direct measures of neoplastic activity, and may be particularly worrisome when we are comparing biologic or hormonal agents with more traditional cytotoxic therapy. A related issue is knowing exactly how to use such a marker to assess benefit. Is it the size of the change (absolute or relative to baseline level) that is important, or whether normal levels are achieved (and/or for how long), or the proportion of patients achieving a desired level? The size of the treatment benefit, and therefore the interpretation of the results of comparative trials, may be very dependent on the way the endpoint is defined.
As the examples demonstrate, these problems are by no means purely theoretical. Fatal adverse effects are sometimes observed in studies evaluating adjuvant therapies for surgically resected tumours, precisely the type of long-term study in which intermediate endpoints would be attractive. In these studies, tumour recurrence is often the primary endpoint. This is a sensible approach, since the intent of adjuvant therapy is to improve the probability that the patient has in fact been cured of neoplastic disease. Nevertheless, the importance of obtaining the ultimate survival results cannot be overstated. The serious side effects, including drug-induced leukaemias, that have been reported for some of these agents (Reimer et al., 1977; Bergsagel et al., 1979; Coltman & Dixon, 1982; Boice et al., 1983) point to the need to verify overall benefit with respect to survival.
An important practical issue concerning the use of surrogate endpoints is that of measurement variability. Other than death, all outcomes are assessed with some degree of uncertainty, due to some combination of measurement error and inherent within-subject biologic variability. The level of uncertainty of any given measure must be taken into account when considering its potential reliability as a trial endpoint. The imprecision of manual and radiologic measurements of tumour size has been well documented (Moertel & Hanley, 1976; Lavin & Flowerdew, 1980; Warr et al., 1984) ; laboratory measures are likely to be at least as variable. While variability can always be reduced by replicate measurements at the defined time points, this approach is often impractical because of financial constraints as well as patient unwillingness to provide multiple samples. The variability of an outcome measure should be an important factor in any decision to use this measure as a basis for definitive evaluation of new therapies, especially when studies are non blinded and when the determination of the measure is at all subjective.
Recently, the use of laboratory markers as trial endpoints has received a great deal of discussion. Some widely used markers such as carcinoembryonic antigen (CEA) in colorectal cancer and CA 125 in ovarian cancer have been shown to be inadequately predictive for this purpose (Fayers et al. (1993) , Ellenberg & Hamilton (1989) , NIH Consensus Conference (1981)). There has been increasing interest in prostate-specific antigen (PSA) which has been shown to be highly correlated with tumour volume in men with prostatic cancer (Stamey et al., 1987) . Since much prostate cancer is non measurable, the availability of a reliable laboratory marker would greatly expand the patient population for Phase II studies to determine tumour activity. For definitive evaluation of clinical benefit, however, it is less clear that this marker or other markers will obviate the need to perform survival studies. While there are ample data to demonstrate the prognostic value of PSA, as exist for CEA and CA 125 as well, data demonstrating that advanced-stage patients who experience the largest treatment-induced reductions in PSA level, or those early patients who experience treatmentprolonged intervals of PSA negativity, will in fact have a lower risk of death, are only now beginning to emerge (Gerber et al., 1990; Seidman et al., 1992; Scher et al., 1992) . Until such data are fully available and are shown to be consistent across treatments, determining relative efficacy of therapeutic approaches on the basis of PSA will remain problematic.
These issues have been widely discussed in the AIDS context (Weiss & Mazade, 1990; Machado et al., 1990; Jacobson et al., 1991; Ellenberg, 1991; Lagakos & Hoth, 1992) . The CD4+ lymphocyte count is a well documented predictor of outcome in HIV-infected patients, but changes in this marker do not appear to be as highly correlated with clinical progression and survival as one would like in order to use this marker as a basis for evaluating and comparing therapeutic efficacy (De Gruttola et al., in press; Tsiatis et al., 1992; Choi et al., 1993) . This may be partially due to the fact that measurements of CD4 + cells are known to be highly variable (Weiss & Mazade, 1990; Taylor et al., 1989; Gelman et al., in press ). However, the recently reported result that in a large placebo-controlled trial of zidovudine in asymptomatic HIV-infected individuals, the CD4 + count was affected, but clinical progression and mortality were not (Aboulker & Swart, 1993) , raises more doubts that this marker can serve as a reliable surrogate for clinical outcomes.
Nevertheless, as in prostate cancer, changes in the marker are well established as indicators of advancing disease, and are frequently used by physicians to determine when modification of the therapeutic approach may be required. In this situation it becomes more difficult to conduct trials using clinically meaningful endpoints, since changes in therapy mandated by these earlier marker events may blur any comparison based on later clinical endpoints.
In both AIDS and cancer, there exists a real sense of urgency to evaluate promising therapies and to make widely available those that prove efficacious. There are certainly risks inherent in waiting longer for answers from survivalbased trials; current patients may be deprived of improved treatments. Such concerns must be weighed against the risk of adopting therapies on the basis of early data without the assurance that current as well as future patients will ultimately benefit from them.
